RT Journal Article
SR Electronic
T1 Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4259
OP 4263
VO 35
IS 7
A1 YASUNORI ENOMOTO
A1 HIROTSUGU KENMOTSU
A1 NAOHIRO WATANABE
A1 TOMOHISA BABA
A1 HARUYASU MURAKAMI
A1 KIYOTAKA YOH
A1 TAKASHI OGURA
A1 TOSHIAKI TAKAHASHI
A1 KOICHI GOTO
A1 TERUFUMI KATO
YR 2015
UL http://ar.iiarjournals.org/content/35/7/4259.abstract
AB Aim: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) with pre-existing interstitial lung disease (ILD). Patients and Methods: Twenty-five patients with non-squamous NSCLC with ILD who underwent CPB therapy between March 2007 and July 2013 were analyzed for treatment profiles. Results: The median age was 67 (range=53-79) years and 96% were men. The triplet chemotherapy was repeated for a median of four cycles. The objective response rate was 72% (18/25), the median progression-free survival time was 7.2 months, and the median overall survival time was 8.5 months. The most frequent adverse event of grade 3 or more was neutropenia (72%, 18/25). Chemotherapy-induced acute exacerbation of ILD occurred in 12% of patients. Conclusion: CPB therapy may be an effective and feasible regimen even for patients with ILD, although clinicians should be concerned regarding neutropenia and acute exacerbation of ILD.